OCT 09, 2019 2:19 PM PDT

Drug Increases Survival Rates for Heart Failure Patients

WRITTEN BY: Nouran Amin

Scientists have demonstrated in preclinical studies that a drug called ‘Aliskiren’ works by inhibiting the activity of an enzyme involved in blood pressure changes. The drug can delay the progression of congestive heart failure and lengthen survival rates.

Caption and Image Credit (University of Arizona): The treated image shows improved contractility of the heart, less ventricle/chamber dilation and improvement in wall thickness compared to the untreated heart.

"This FDA-approved drug has the potential to improve the quality and extend the life in properly identified heart failure patients," said Ryan Sullivan, DVM, assistant professor in the college's Department of Internal Medicine and lead author of the study, "Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival," published in the August 2019 edition of the International Journal of Molecular Sciences, as part of a Special Issue Heart Failure: From Molecular Basis to Therapy.

Currently, more than 5 million Americans live with congestive heart failure, a chronic progressive condition characterized by the inability for the heart to pump adequate blood through the body.

"That's an extra 5.6 years with loved ones that otherwise would not be possible. Obviously, further studies are needed, along with human clinical trials, but we are excited about our research direction and what those outcomes could mean for the college and the people of Arizona and beyond."

Learn more about heart failure:

"Heart failure is a rapidly increasing cause of disability and death," Dr. Sullivan said. "Patients suffer from progressive muscle wasting and fluid retention, which leads to discomfort, shortness of breath and fatigue. There is a need to better measure muscle wasting and fluid retention to identify effective methods for treatment and prevention. These exciting findings demonstrate new approaches that may guide future care for heart failure patients."

Source: University of Arizona

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 29, 2022
Drug Discovery & Development
Kicking Pro-tumor Immune Cells Out of the Microenvironment
Kicking Pro-tumor Immune Cells Out of the Microenvironment
Tumors use our own immune systems against us by coaxing regulatory T cells to keep antitumor immune response low. But re ...
DEC 11, 2022
Immunology
The First Drug That Can Delay Type 1 Diabetes Onset is Approved
The First Drug That Can Delay Type 1 Diabetes Onset is Approved
About 30,000 people are diagnosed with type 1 diabetes every year in the United States, and it's a common chronic diseas ...
DEC 11, 2022
Drug Discovery & Development
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
A monoclonal antibody drug known as rocatinlimab produced significant results in patients with moderate to severe atopic ...
JAN 05, 2023
Neuroscience
Fear Memories are Stored in Prefrontal Cortex
Fear Memories are Stored in Prefrontal Cortex
A University of California, Riverside research team examined how the brain processes and stores memories of traumatic ex ...
JAN 28, 2023
Drug Discovery & Development
Parkinson's Drug May Reduce Brain Inflammation from Depression
Parkinson's Drug May Reduce Brain Inflammation from Depression
Levodopa, a drug used to increase dopamine levels in people with Parkinson’s disease, may also reverse the effects ...
JAN 31, 2023
Drug Discovery & Development
A Whipped Jet Aerosol Sprayer that could Change Drug Discovery
A Whipped Jet Aerosol Sprayer that could Change Drug Discovery
A whipped jet aerosol sprayer that has the potential to revolutionize everything from the pharmaceutical to automobile i ...
Loading Comments...